The presence of mucous secretions with abnormal viscoelastic properties of the tracheobronchial tree is the most widely known feature of patients with cystic fibrosis (CF). This results in the obstruction of the lung airways and leads to chronic pulmonary disease which is responsible for most of the mortality in CF patients. The objectives of this research proposal are to investigate the basis of altered viscoelastic properties of the CF secretions. The specific objectives are a) to determine if the altered viscoelastic properties of CF tracheobronchial secretions correlate with changes in the biochemical composition (e.g., increased level of sulfation of CF mucin as compared to normal mucin) or with changes in biophysical properties of mucin molecules (e.g., molecular aggregation characteristics and mucin conformation) and b) determine the effect of non-mucin components present in the secretions, such as serum proteins (especially albumin, lysozyme, IgG, etc.), and polycations [Ca2+, polyamines (putrescine, spermidine and spermine) and low molecular weight basic proteins(s)] on the molecular aggregation and viscoelastic properties of the mucins. For these studies, the native and reduced mucin and non-mucin components will be purified from tracheobronchial secretions collected from a) CF patients; b) age and sex matched normal controls including normal siblings of CF patients and c) age and sex matched patients with bronchitis and asthma, using protocols established in this laboratory. Biochemical characterization of purified components will include: determination of carbohydrate, sulfate, amino acid composition, disulfide bond content, relative charge and molecular weight of the components. For biophysical characterization of the purified components of CF and control secretions, we will determine hydrophobic binding sites using fluorescence probe technique and molecular aggregation of mucins and other components using highly sensitive and versatile fluorescence polarization and light scattering techniques. Light scattering will be used to determine molecular weight of mucins, and of mucin aggregates as well as for determining conformation of mucin molecules (i.e. from radius of gyration determination). The viscoelastic properties will be determined using a magnetic microrheometer. These studies will aid in the understanding of underlying mechanism(s) responsible for abnormal viscoelastic properties of the CF secretions. Also, knowledge from studies will facilitate the development of a rational approach to the treatment of chronic lung disease in CF which ultimately must require an ability to control the viscoelastic properties, rate of secretion and elimination of the secretions.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL034012-03
Application #
3346514
Study Section
Biochemistry Study Section (BIO)
Project Start
1984-07-01
Project End
1987-06-30
Budget Start
1986-07-01
Budget End
1987-06-30
Support Year
3
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Type
Schools of Pharmacy
DUNS #
937727907
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Damera, Gautam; Xia, Baoyun; Sachdev, Goverdhan P (2006) IL-4 induced MUC4 enhancement in respiratory epithelial cells in vitro is mediated through JAK-3 selective signaling. Respir Res 7:39
Damera, Gautam; Xia, Baoyun; Ancha, Hanumatha R et al. (2006) IL-9 modulated MUC4 gene and glycoprotein expression in airway epithelial cells. Biosci Rep 26:55-67
Hebbar, Vidya; Damera, Gautam; Sachdev, Goverdhan P (2005) Differential expression of MUC genes in endometrial and cervical tissues and tumors. BMC Cancer 5:124
Shankar, V; Pichan, P; Eddy Jr, R L et al. (1997) Chromosomal localization of a human mucin gene (MUC8) and cloning of the cDNA corresponding to the carboxy terminus. Am J Respir Cell Mol Biol 16:232-41
Shankar, V; Gilmore, M S; Sachdev, G P (1995) Further evidence that the human MUC2 gene transcripts in the intestine and trachea are identical. Biochem J 306 ( Pt 1):311-2
Shankar, V; Gilmore, M S; Elkins, R C et al. (1994) A novel human airway mucin cDNA encodes a protein with unique tandem-repeat organization. Biochem J 300 ( Pt 2):295-8
Padhye, N V; Shankar, V; Reyes de la Rocha, S et al. (1994) Biophysical characterization of mucin components HTM-1 and HTM-2 from tracheobronchial secretions of cystic fibrosis patients. Biochim Biophys Acta 1209:56-60
Desai, V C; Shankar, V; de la Rocha, S R et al. (1993) Peptide mapping reveals differences in the non-glycosylated domains of cystic fibrosis and normal tracheobronchial mucins. Indian J Biochem Biophys 30:382-8
Desai, V C; Naziruddin, B; Graves, D C et al. (1991) Production and characterization of monoclonal antibodies to purified deglycosylated cystic fibrosis respiratory mucin: evidence for the presence of four immunologically distinct epitopes. Hybridoma 10:285-96
Padhye, N V; Naziruddin, B; Desai, V C et al. (1991) Physicochemical characterization of a minor mucin component from cystic fibrosis tracheobronchial secretions. Biochim Biophys Acta 1077:332-8

Showing the most recent 10 out of 14 publications